Now showing items 1-2 of 2

    • Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. 

      Muranen, TA; Greco, D; Blomqvist, C; Aittomäki, K; Khan, S; Hogervorst, F; Verhoef, S; Pharoah, PDP; Dunning, AM; Shah, M; Luben, R; Bojesen, SE; Nordestgaard, BG; Schoemaker, M; Swerdlow, A; García-Closas, M; Figueroa, J; Dörk, T; Bogdanova, NV; Hall, P; Li, J; Khusnutdinova, E; Bermisheva, M; Kristensen, V; Borresen-Dale, A-L; NBCS Investigators; Peto, J; Dos Santos Silva, I; Couch, FJ; Olson, JE; Hillemans, P; Park-Simon, T-W; Brauch, H; Hamann, U; Burwinkel, B; Marme, F; Meindl, A; Schmutzler, RK; Cox, A; Cross, SS; Sawyer, EJ; Tomlinson, I; Lambrechts, D; Moisse, M; Lindblom, A; Margolin, S; Hollestelle, A; Martens, JWM; Fasching, PA; Beckmann, MW; Andrulis, IL; Knight, JA; kConFab/AOCS Investigators; Anton-Culver, H; Ziogas, A; Giles, GG; Milne, RL; Brenner, H; Arndt, V; Mannermaa, A; Kosma, V-M; Chang-Claude, J; Rudolph, A; Devilee, P; Seynaeve, C; Hopper, JL; Southey, MC; John, EM; Whittemore, AS; Bolla, MK; Wang, Q; Michailidou, K; Dennis, J; Easton, DF; Schmidt, MK; Nevanlinna, H (2017-05)
      Purpose CHEK2*1100delC is a founder variant in European populations that confers a two- to threefold increased risk of breast cancer (BC). Epidemiologic and family studies have suggested that the risk associated with ...
    • Synthetic Lethality and Cancer - Penetrance as the Major Barrier. 

      Ryan, CJ; Bajrami, I; Lord, CJ (2018-10)
      Synthetic lethality has long been proposed as an approach for targeting genetic defects in tumours. Despite a decade of screening efforts, relatively few robust synthetic lethal targets have been identified. Improved genetic ...